

# Canada's Premiere Virtual Cardiovascular Symposium

CardioMet'25 will be Canada's premiere, virtual cardiovascular symposium. Aimed at cardiovascular specialists, this multi-day virtual conference will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'25 will be unlike any other cardiovascular conference in Canada.

**31st JANUARY**  
**7th FEBRUARY** 2025

**12:00 – 6:00 pm EST**

## Program Themes

### 31st JANUARY 2025

- ARRHYTHMIA
- HEART FAILURE
- CARDIOMYOPATHIES AND CARDIOGENIC SHOCK

### 7th FEBRUARY 2025

- CHRONIC CORONARY SYNDROMES
- CARDIOMETABOLIC
- POT POURRI

**Register Now!**

## Accreditation:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the University of Calgary Office of Continuing Medical Education and Professional Development. This activity has been approved for a maximum of 10.5 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

# CardioMet<sup>'25</sup>

## Scientific Planning Committee



### Margot Davis

MD, FRCP, FCCS  
University of British Columbia



### Anique Ducharme

MD, MSc, FRCP, FCCS  
Montreal Heart Institute



### Milan Gupta

MD, FRCPC, FCCS, CPC(HC)  
University of Toronto



### Jay Udell

MD, MPH, FRCPC  
Toronto General Hospital

## Overall Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention
- ✓ Explain new developments in the management of heart failure, cardiomyopathies and arrhythmia
- ✓ Explore advances in chronic coronary syndromes and cardiometabolic medicine

## Registration

Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

For inquiries regarding this program, please contact [info@ccrnmd.com](mailto:info@ccrnmd.com).



This program has received an educational grant from:

**Impact Level:** Pfizer, Egg Farmers of Canada, Novartis, Merck

**Benefactor Level:** Amgen, Bayer, Anthos Therapeutics

# PROGRAM AGENDA

Friday, January 31st, 2025



CardioMet<sup>'25</sup>



## Faculty

12:00 - 12:10 Welcome and opening remarks

Milan Gupta

### KEYNOTE ADDRESS

12:10 - 12:35 Global perspective on CVD : Rethinking its causes

Salim Yusuf

12:35 - 12:45 DISCUSSION

### THEME ONE ARRHYTHMIA

12:45 - 1:03 How to manage post-operative atrial fibrillation

William McIntyre

1:03 - 1:21 AF: antiarrhythmic therapy or ablation?

Laurent Macle

1:21 - 1:39 Factor XI/XIa inhibitors – are they the future?

C. Michael Gibson

1:39 - 1:57 PVC's/VT – when to ablate?

Isabelle Nault

1:57 - 2:20 DISCUSSION

### Learning Objectives

- Examine the impact of diet, risk factors, health systems and the environment on cardiovascular disease
- Describe prevention and management strategies for post-operative atrial fibrillation
- Determine when to ablate vs the role of antiarrhythmic therapy for AF
- Explore the role of Factor XI/XIa in AF stroke prevention and bleeding
- Identify when ablation is appropriate for PVC's/VT

2:20 - 2:45 REFRESHMENT BREAK

### THEME TWO HEART FAILURE

2:45 - 3:03 HFpEF and the obesity/inflammation continuum

Mark Petrie

3:03 - 3:21 HFpEF: what's on the horizon?

Scott Solomon

3:21 - 3:39 Pulmonary hypertension: a primer for cardiologists

Lisa Mielniczuk

3:39 - 3:57 Challenging cases in HFrEF

Margot Davis

3:57 - 4:20 DISCUSSION

### Learning Objectives

- Examine the impact of obesity and inflammation for patients with HFpEF
- Explore evolving treatment options for HFpEF
- Define the causes and treatment strategies for pulmonary hypertension
- Apply best practices for the management of challenging HFrEF cases

### THEME THREE CARDIOMYOPATHIES & CARIOGENIC SHOCK

4:20 - 4:38 Investigating LVH: treatment advances in hypertrophic cardiomyopathy

Patrick Garceau

4:38 - 4:56 Infiltrative cardiomyopathies: sarcoid and amyloid

Rola Khedraki

4:56 - 5:14 Cardiogenic shock – early detection and planning ahead

Adriana Luk

5:14 - 5:32 Cardio-rheumatology – Understanding the biology and monitoring for anti-inflammatory therapies in cardiology

Brittany Weber

5:32 - 5:55 DISCUSSION

### Learning Objectives

- Define new treatment options for patients with hypertrophic cardiomyopathy
- Explore the diagnostic and management strategies for infiltrative cardiomyopathies
- Explain strategies for managing cardiogenic shock to improve outcomes
- Describe the biology and need for monitoring of anti-inflammatory therapies in cardio-rheumatology

5:55 - 6:00 MEETING CLOSE

Faculty

12:00 - 12:10 Welcome and opening remarks **Milan Gupta**

**KEYNOTE ADDRESS**

12:10 - 12:30 Womens' health and cardiovascular medicine **Martha Gulati**

12:30 - 12:40 DISCUSSION

**THEME ONE CHRONIC CORONARY SYNDROMES**

12:40 - 12:58 DM and CKD management in patients with ASCVD **Matthew R. Weir**

12:58 - 1:16 Obesity management in patients with ASCVD **Milan Gupta**

1:16 - 1:34 How to best investigate stable CAD in 2025 **Michael E. Farkouh**

1:34 - 1:52 Stable multivessel disease: OMT, PCI or CABG? **John Mancini**

1:52 - 2:15 DISCUSSION

**Learning Objectives**

- Examine issues unique to women in the prevention and management of cardiovascular disease
- Explain how to manage diabetes and CKD in patients with ASCVD
- Explain how to manage obesity in patients with ASCVD
- Identify effective methods for detecting coronary artery disease
- Determine appropriate treatment or intervention for patients with stable multivessel disease

2:15 - 2:45 **REFRESHMENT BREAK**

**THEME TWO CARDIOMETABOLIC**

2:45 - 3:03 The role of dietary cholesterol in ASCVD **Kristina S. Petersen**

3:03 - 3:21 LDL-C: how low can and should we go? **Marc Sabatine**

3:21 - 3:39 Triglycerides: the forgotten risk marker **Liam Brunham**

3:39 - 3:57 Elevated Lp(a): how to manage in primary and secondary prevention **Michelle O'Donoghue**

3:57 - 4:20 DISCUSSION

**Learning Objectives**

- Examine the impact of dietary cholesterol on ASCVD
- Determine the appropriate LDL-C level for at-risk patients
- Explore current and future treatment options for risk reduction with elevated triglycerides
- Explore the potential of Lp(a) lowering in primary and secondary prevention

**THEME THREE POT POURRI**

4:20 - 4:38 MINOCA/INOCA: diagnosis and management **Tara Sedlak**

4:38 - 4:56 POTS: diagnosis and management **Satish R. Raj**

4:56 - 5:14 Adult congenital heart disease for the general cardiologist **Jasmine Grewal**

5:14 - 5:32 Cardio-oncology for the general cardiologist **Dinesh Thavendiranathan**

5:32 - 5:55 DISCUSSION

**Learning Objectives**

- Describe an approach to diagnosis and treatment of MINOCA
- Explain when and how to suspect and confirm a diagnosis of POTS
- Explain the role of general cardiologist in patients with congenital heart disease
- Explore clinical lessons for general cardiologists managing patients with cancer

5:55 - 6:00 **MEETING CLOSE**



**Registration**  
Visit: [www.ccrnmd.com](http://www.ccrnmd.com)

**Register Now!**

